泰山石化(01192.HK)补回公布附属曾斥940万人币向关连方购综合服务业务权益
泰山石化(01192.HK)公布,间接全资附属泰山企业管理谘询曾於2017年12月28日与张谦东订立股权转让协议,对方以总代价940万元人民币将上海耀炫之全部股本转让予泰山企业管理谘询。
张谦东在相关时刻为上海耀炫之唯一股东,以及公司之主要股东华汇资本的最终实益拥有人。
上海耀炫於合资公司持有的20%股权,合资公司打算依托中国上海市虹口区北外滩的政策及区位优势,提供船舶修理、船舶建造、船舶改装、海工建设及海事服务的综合服务业务。
根据上市规则第14A章,延迟刊发公告构成公司的不合规行为。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.